Abstract LB197: Tucatinib has selective activity in HER2-positive cancers and significant combined activity with approved and novel breast cancer targeted therapies

曲妥珠单抗 医学 肿瘤科 乳腺癌 帕妥珠单抗 癌症 内科学 药理学 癌症研究
作者
Neil A. O’Brien,Holly K. Huang,Martina S.J. McDermott,Athena M. Madrid,Tong Luo,Raul Ayala,Shawnt Issakhanian,Ke Wei Gong,Ming Lu,Jun Zhang,Dennis J. Slamon
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:82 (12_Supplement): LB197-LB197
标识
DOI:10.1158/1538-7445.am2022-lb197
摘要

Abstract Pharmacologically targeting the HER2 oncoprotein with therapeutics such as the monoclonal antibody (mAb), trastuzumab, provides clinical benefit for patients with HER2-positive (HER2+) cancers. However, a significant number of patients eventually progress on these therapies. Efforts to overcome therapeutic resistance through combination therapy with small molecule inhibitors of HER2 have been limited by toxicities associated with off-target activity and/or limited efficacy. In this preclinical study, we explore single-agent and combined activity of tucatinib, a novel HER2-selective small molecule inhibitor. Tucatinib demonstrated potent, selective activity in a panel of 456 human cancer cell lines, with activity restricted to cell lines (breast and non-breast) with HER2-amplification, including models of acquired resistance to trastuzumab. Within the HER2+ population, tucatinib response tracked strongly with HER2-driven signaling. Single agent tucatinib induced tumor regressions in xenograft models of HER2+ breast cancer and combination with trastuzumab induced a complete and sustained blockade of HER2/PI3K/AKT-signaling. Efficacy of the tucatinib/trastuzumab combination matched that induced by current standard of care (SOC) trastuzumab/pertuzumab/docetaxel combination, with the exception that the chemotherapy-sparing tucatinib/trastuzumab combination did not require a dosing holiday to achieve the same efficacy. In xenograft models of HER2+ breast cancer that also express estrogen receptor (ER) (HER2+/ER+), tucatinib showed combined efficacy with inhibitors of CDK4/6 and ER, indicating potential novel therapeutic strategies for difficult-to-treat subtypes of HER2+ breast cancer. These data support expanded clinical investigations of tucatinib as a combination partner for other novel and approved targeted therapies for HER2-driven malignancies. Citation Format: Neil A. O'Brien, Holly K. Huang, Martina S. McDermott, Athena Madrid, Tong Luo, Raul Ayala, Shawnt Issakhanian, Ke Wei Gong, Ming Lu, Jun Zhang, Dennis J. Slamon. Tucatinib has selective activity in HER2-positive cancers and significant combined activity with approved and novel breast cancer targeted therapies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr LB197.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
sylar完成签到,获得积分10
刚刚
鹰击长空完成签到,获得积分10
刚刚
KKK的科研完成签到 ,获得积分10
刚刚
刚刚
灵机完成签到,获得积分10
1秒前
自由茉莉完成签到 ,获得积分10
1秒前
端庄的萝完成签到,获得积分10
1秒前
1秒前
开放凉面完成签到,获得积分10
2秒前
坚定尔蓝完成签到,获得积分10
2秒前
活泼寒凡完成签到,获得积分10
2秒前
2秒前
1752795896完成签到,获得积分10
2秒前
小胖卷毛完成签到,获得积分0
3秒前
3秒前
薯片完成签到 ,获得积分10
3秒前
月光盏完成签到,获得积分10
4秒前
4秒前
fu完成签到,获得积分10
4秒前
4秒前
along完成签到,获得积分10
4秒前
黄金弗利萨完成签到,获得积分10
4秒前
lic完成签到,获得积分10
4秒前
beiyao11完成签到,获得积分10
5秒前
梁正凤完成签到,获得积分10
5秒前
5秒前
guan完成签到,获得积分10
6秒前
杜凯敏完成签到,获得积分10
6秒前
xinran_lv完成签到,获得积分10
6秒前
王晓完成签到,获得积分10
6秒前
DezhaoWang完成签到,获得积分0
7秒前
小糖缘完成签到,获得积分10
7秒前
瘦瘦书本完成签到,获得积分10
7秒前
liu完成签到 ,获得积分10
7秒前
手机吧唧一丢完成签到,获得积分10
7秒前
盼烟完成签到,获得积分10
7秒前
马颗粒发布了新的文献求助10
8秒前
TED的应助被天真的采纳,获得10
8秒前
珂珂完成签到,获得积分10
8秒前
周艳鸿完成签到,获得积分10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180146
求助须知:如何正确求助?哪些是违规求助? 9570319
关于积分的说明 21809739
捐赠科研通 7776294
什么是DOI,文献DOI怎么找? 3433266
关于科研通互助平台的介绍 2557483
邀请新用户注册赠送积分活动 2479039